Enepret Incorporated
Lexington, KY
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 145 Graham Ave a317, Lexington, KY 40506, USA
- Website
- enepret.com
- Industry
-
- Industrials
- Commercial & Professional Services
- Professional Services
- Consulting
- SIC code
- 73 Business Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $599,526 |
Contract awards
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Amentum Services, Inc. | 80ARC024DA004 | $2,372,895 | |
| Amentum Services, Inc. | 80ARC024DA004 | $2,735,976 |
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Evaluating synthetic biology produced triterpene oils in adjuvant formulations | National Institute of Allergy and Infectious Diseases (NIH) | $224,703 |
Similar vendors
About the company
Enepret Incorporated is a for-profit corporate entity based in Lexington, Kentucky, registered in SAM.gov since February 2017. The company operates as a manufacturer of goods with a specialized focus on scientific research and development, particularly in the biomedical and vaccine research domains. Its primary business appears to center on innovative research related to vaccine technologies and adjuvant development, with a keen emphasis on synthetic biology approaches to infectious disease mitigation.
The company has secured significant federal contract awards from the National Institute of Allergy and Infectious Diseases (NIAID), predominantly through the Small Business Innovation Research (SBIR) program. These contracts include a $599,526 Firm Fixed Price contract focused on "Adjuvant Discovery and Down-Selection for Vaccines against Infectious and Immune-Mediated Diseases" with a completion date of May 31, 2027, and a $2,996,311 SBIR Phase II contract for "Production of Adjuvant Mimics" awarded on August 30, 2022. The contracts are notable for their research-oriented nature, targeting innovative vaccine development strategies, particularly in creating more durable and universal influenza vaccine technologies. Enepret has also received a sub-contract award dated December 5, 2024, labeled "CORETEC-3105 FUNDING". The company's federal contract awards have not been set aside for specific socioeconomic programs, except for the SBIR Phase II contract, which had a total small business set-aside designation.
SBA capabilities narrative
Providing reliable, robust, renewable, cost effective production systems for high value terpenes
Quick answers
Is Enepret Incorporated registered in SAM.gov?
Yes. Enepret Incorporated's SAM.gov registration is active through August 6, 2027.
What is Enepret Incorporated's CAGE code?
Enepret Incorporated's CAGE code is 7T4R7, and its Unique Entity ID (UEI) is P3KJFJJR58R4.
How much has Enepret Incorporated received in federal contracts?
Federal contracts obligated $599,526 to Enepret Incorporated in fiscal year 2025.
What is Enepret Incorporated's most recent federal award?
Enepret Incorporated's most recent federal contract award is Adjuvant discovery and down-selection for vaccines against infectious and immune-mediated diseases (75N93025C00020), from National Institute of Allergy and Infectious Diseases (NIH), on June 1, 2025.
On GovTribe
See Enepret Incorporated's full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors